Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

990 - Circulating Cell Free DNAas a Biomarker in the Serum of Colorectal Cancer Patients (49P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Alshimaa Alhanafy

Citation

Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653

Authors

A.M. Alhanafy1, M. El Shafei2, M. Safan2, E. Elnour2, M. Habib2, T. Rageh3, A. Salah El-Din2

Author affiliations

  • 1 Department Of Clinical Oncology And Nuclear Medicine, Menoufia University , Faculty of Medicine, 32511 - Shebin El Kom/EG
  • 2 Department Of Medical Biochemistry, Menoufia University , Faculty of Medicine, 32511 - Shebin El Kom/EG
  • 3 Department Of General Surgery, Menoufia University , Faculty of Medicine, 32511 - Shebin El Kom/EG
More

Resources

Abstract 990

Background

Cell-free DNA is extracellular nucleic acids found in cell-free plasma/serum of humans. Circulating extracellular DNA can be found in healthy persons, persons with nonmalignant diseases, as well as persons with various malignancies. Given the recent approval of a liquid biopsy, the use of circulating tumor DNA as a novel and non-invasive test for the diagnosis and surveillance of cancer is a rapidly growing area of interest.

Methods

This study was carried out in Menoufia University hospital in the period from May 2015 to December 2015. It was conducted on 80 individuals classified into: Group I: included 40 colorectal cancer (CRC) patients Group II: included 20 patients with colorectal benign diseases. Group III: included 20 healthy controls. Laboratory investigations including detection of quantitative analysis of circulating cell free DNA (ccf-DNA) through detection of short (115bp) DNA fragments in serum by real time quantitative PCR by amplifying the ALU repeats (ALU-qPCR) and CA19 9 serum level by ELISA.

Results

There was significant statistical difference in serum level of ALU 115 between group I (1123.8±356.3) and both of group II (432.2±147.8) and III (317±105) both (p = 0.001), where there was non-significant statistical difference in serum levels ALU 115 between group II & III (p = 0.180). There was significant statistical difference in serum level of CA19-9 between group I (42.4±92.3) and both of group II (10.5±5.87) (p = 0.032) and III (9.74±5.62) (p = 0.013), where there was non-significant statistical difference in serum levels of CA19-9 between group II & III (p = 0.684). The diagnostic accuracy for distinguishing primary CRC patients from normal control by ALU 115 is (85%), with sensitivity (83%), specificity (90%), positive predictive value (96%) and negative predictive value (64%) at cut off point of 426 ng/ml. The diagnostic accuracy by CA19-9 is (59%), with sensitivity (60%), specificity (55%), positive predictive value (80%) and negative predictive value (31%) at cut off point of 8.45 U/ml. combined detection of ALU115 and CA19-9 improved the sensitivity to (88%). There was a significant positive correlation between ALU 115 serum level and tumor grade (p = 0.024), also between CA19-9 and primary tumor stage and presence of metastases (p = 0.012) and (p = 0.044).

Conclusions

It was concluded that serum DNA concentrations may be valuable in early diagnosis and monitoring of colorectal cancer patients.

Clinical trial identification

Legal entity responsible for the study

Menoufia University

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings